These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 12142552)
1. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. Zhou Y; Bosch ML; Salgaller ML J Immunother; 2002; 25(4):289-303. PubMed ID: 12142552 [TBL] [Abstract][Full Text] [Related]
2. Loading DCs with Ag. Vari F; Hart DN Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987 [TBL] [Abstract][Full Text] [Related]
3. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385 [TBL] [Abstract][Full Text] [Related]
4. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847 [TBL] [Abstract][Full Text] [Related]
5. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
6. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H Med Oncol; 2006; 23(2):273-82. PubMed ID: 16720928 [TBL] [Abstract][Full Text] [Related]
8. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity. Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW Front Immunol; 2018; 9():822. PubMed ID: 29755461 [TBL] [Abstract][Full Text] [Related]
9. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Salem ML Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701 [TBL] [Abstract][Full Text] [Related]
10. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678 [TBL] [Abstract][Full Text] [Related]
11. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells. Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671 [TBL] [Abstract][Full Text] [Related]
12. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582 [TBL] [Abstract][Full Text] [Related]
13. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity. Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232 [TBL] [Abstract][Full Text] [Related]
14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
15. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812 [TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492 [TBL] [Abstract][Full Text] [Related]
18. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291 [TBL] [Abstract][Full Text] [Related]
19. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
20. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]